ACADIA Pharmaceuticals: Mixed Fourth-Quarter Results
ACADIA Pharmaceuticals, a biopharmaceutical company specializing in neurological and psychiatric disorders, recently reported mixed results for the fourth quarter of 2021. While earnings missed analysts’ estimates, revenues managed to surpass expectations, thanks to robust year-over-year growth in the sales of Nuplazid and Daybue.
Missed Earnings but Beat Revenue Estimates
The company reported earnings of $0.15 per share, which fell short of the estimated $0.18 per share by analysts. However, revenues came in at $181.8 million, which was higher than the projected $179.3 million.
Driving the Revenue Growth: Nuplazid and Daybue
The growth in revenues can be attributed to the stellar performance of two of ACADIA’s key drugs: Nuplazid and Daybue. Nuplazid, a treatment for Parkinson’s disease psychosis, recorded sales of $168.2 million, marking a 17% increase from the same period last year. Daybue, an intravenous formulation of risperidone, used for the treatment of agitation in patients with dementia-related psychosis, generated sales of $13.6 million, representing a 41% increase from the previous year.
Impact on Investors
The mixed quarterly results led to a slight dip in ACADIA’s stock price, with shares falling by approximately 3% in after-hours trading following the earnings announcement. However, the strong sales growth in Nuplazid and Daybue could potentially offset these concerns for investors.
Global Implications
The success of Nuplazid and Daybue in the US market could pave the way for their approval and commercialization in other regions. This expansion could significantly boost ACADIA’s revenue growth and broaden its reach in the global market.
Conclusion
ACADIA Pharmaceuticals’ fourth-quarter results presented a mixed bag, with earnings missing the mark but revenues surpassing expectations. The company’s growth in Nuplazid and Daybue sales offers promising prospects for investors and the potential for further global expansion. Despite the slight dip in stock price following the earnings announcement, the strong sales performance of these two drugs could help mitigate concerns and maintain investor confidence.
- ACADIA Pharmaceuticals reported mixed fourth-quarter results.
- Earnings missed estimates, but revenues beat expectations.
- Nuplazid and Daybue sales contributed to the revenue growth.
- The success of these drugs in the US market could lead to global expansion.
- Investor sentiment remains mixed following the earnings announcement.
